233 results on '"Demir, Münevver"'
Search Results
2. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
3. Antibiotic therapy is associated with an increased incidence of cancer
4. A global research priority agenda to advance public health responses to fatty liver disease
5. Treating hepatitis D with bulevirtide – Real-world experience from 114 patients
6. Nonalcoholic Steatohepatitis Disrupts Diurnal Liver Transcriptome Rhythms in Mice
7. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
8. Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
9. An elevated FIB-4 score is associated with an increased incidence of liver cancer: A longitudinal analysis among 248,224 outpatients in Germany
10. NAFLD and cardiovascular diseases: a clinical review
11. An elevated FIB-4 score is not associated with cardiovascular events: a longitudinal analysis from 137 842 patients with and without chronic liver disease
12. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
13. Incidences of hypothyroidism and autoimmune thyroiditis are increased in patients with nonalcoholic fatty liver disease
14. Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
15. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease.
16. Chapter 13 - Turmeric starch: structure, functionality, and applications
17. Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming
18. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools
19. Liver fat as risk factor of hepatic and cardiometabolic diseases.
20. Management of alcoholic hepatitis: A clinical perspective.
21. Skeletal Muscle Composition Predicts Outcome in Critically Ill Patients
22. Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers
23. Validation of risk scores for allograft failure after liver transplantation in Germany: a retrospective cohort analysis
24. FRI-549 - Soluble urokinase plasminogen activator receptor is a biomarker for outcome in decompensated liver cirrhosis and acute-on-chronic liver failure
25. Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial
26. Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B
27. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort.
28. Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome.
29. Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
30. Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed.
31. TOP-003-YI Model for end-stage liver disease score-based liver allocation is associated with reduced survival in low donation countries-a comparative analysis between Germany and the USA
32. SAT-135 Soluble urokinase plasminogen activator receptor (suPAR) levels predict survival in patients with portal hypertension undergoing TIPS
33. Complement activation induces excessive T cell cytotoxicity in severe COVID-19
34. The role of the circadian clock in the development, progression, and treatment of non‐alcoholic fatty liver disease.
35. Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry.
36. List of contributors
37. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis
38. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients
39. Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity
40. Real‐life experiences with bulevirtide for the treatment of hepatitis delta—48 weeks data from a German centre.
41. Nonalcoholic fatty liver disease – current status and future directions
42. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
43. Shear Wave Elastography and Shear Wave Dispersion Imaging in the Assessment of Liver Disease in Alpha1-Antitrypsin Deficiency
44. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of osteoporosis and bone fractures.
45. Telmisartan Plus Propranolol Improves Liver Fibrosis and Bile Duct Proliferation in the PSC-Like Abcb4−/− Mouse Model
46. The laparoscopic approach for radiofrequency ablation of hepatocellular carcinoma—indication, technique and results
47. Perinatal Obesity Induces Hepatic Growth Restriction with Increased DNA Damage Response, Senescence, and Dysregulated Igf-1-Akt-Foxo1 Signaling in Male Offspring of Obese Mice.
48. An Elevated FIB-4 Score Is Associated with an Increased Incidence of Depression among Outpatients in Germany.
49. The fecal mycobiome in non-alcoholic fatty liver disease.
50. In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.